Search Results

Get private biotech scaling memos—exclusive strategy notes not shared publicly. Short, tactical memos for CEOs and operators to fix bottlenecks, scale teams, and speed up timelines. Book a Strategy Call Get New Memos by Email Built for BioTech operators • 10–100 FTE • Boston & global Hiring scales faster than processes → hidden ops debt. FAQ Q1: What is the Biotech Scaling Vault?

Scaling is the silent killer in biotech. Create a RACI map (Responsible, Accountable, Consulted, Informed) for the top 10 workflows. Scaling requires generalists who build systems. Alignment (how consistent board updates are with internal execution). The Discipline of “No” Scaling companies fail by chasing parallel programs.

We Build Real Strategy in Real Time, With Your Team. 🚫 No fluff. 🚫 No 200-page decks. 🚫 No “consultant Some biotech teams are still figuring out what they want to be when they grow up, and others are growing This isn’t consulting-as-usual. Attila Foris 10 hours ago 4 min read From Startup to Scale-Up: How to Overcome Biotech Scale-Up Challenges 👉 Scaling up is the critical inflection point for any biotech company.

Why Scaling Up Is So Difficult in Biotech The transition from startup to scale-up is often described The Most Common Biotech Scale-Up Challenges When a biotech company moves from startup to scale-up, it Practical Strategies to Overcome Biotech Scale-Up Challenges While the path from startup to scale-up 👉Strategic partnerships with contract manufacturers, regulatory consultants, or supply chain experts Attila runs focused strategy consultations for biotech founders  who are ready to lead with clarity,

Biotech CEOs hit a wall not when science fails, but when operations can’t keep up. The scaling cliff is real: a company that thrived at 20 people collapses under the weight of 80. In reality, scaling operations is a structural shift, not a linear one. Scaling operations means building systems of accountability  before the talent density erodes. Signal 3: Why Biotech Scaling Operations Matter to Investors Capital is no longer chasing just IP.

Scaling Framework: In biotech, failure rarely comes from the science. It comes from the inability to scale beyond the lab. It’s “Can the company scale?” holding up enterprise value : Pipeline Discipline  – Only expand when it compounds efficiency or strengthens Actionable Takeaway Stop confusing expansion with scale.